obliga

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

oursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Malley Thomas					2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023									r (give title		Other (s below)	·			
C/O KURA ONCOLOGY, INC. 12730 HIGH BLUFF DRIVE, SUITE 400				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person								
(Street)	Street) SAN DIEGO CA 92130													Form filed by More than One Reporting Person							
(City)	(S	,	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										d to						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transar Date (Month/Date			saction	ction 2A. Deemed Execution Date,			Transaction Disposed Of (Disposed Of (Dispos		ties Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amo Securit Benefic	nt of es ally -ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership						
								Code	v	Amount	(A) or (D) Price		Transa	saction(s) : 3 and 4)			(Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisable	Exp	oiration e	Title	Amount or Number of Shares								
Option to purchase common stock	\$13.32	05/31/2023			A		26,000		(1)	05/3	30/2033	Common Stock	26,000	\$0.00	26,000)	D				

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

Remarks:

Teresa Bair, Attorney-in-fact for Thomas Malley

06/02/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.